MedPath

AZD-3427

Generic Name
AZD-3427

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Jul 3, 2025

AZD-3427: A Comprehensive Analysis of a Novel Long-Acting Relaxin Mimetic for Heart Failure and Pulmonary Hypertension

Executive Summary

AZD-3427 is a first-in-class, investigational, long-acting relaxin mimetic being developed by AstraZeneca as a potential therapy for heart failure (HF) and associated pulmonary hypertension (PH). Engineered as a human recombinant Fc fusion protein, AZD-3427 is designed to overcome the critical limitation of its short-acting predecessors—a short plasma half-life—thereby enabling chronic subcutaneous administration for sustained therapeutic effect. The drug selectively targets the relaxin family peptide receptor 1 (RXFP1), a G-protein coupled receptor whose activation mediates a cascade of beneficial pleiotropic effects, including vasodilation, and anti-inflammatory and anti-fibrotic actions. These mechanisms are highly relevant to the complex pathophysiology of cardiorenal disease.

The development of AZD-3427 represents a significant strategic pivot, shifting the therapeutic paradigm for relaxin-based therapies from acute, in-hospital treatment to chronic, outpatient disease modification. This strategy is informed by the mixed results of earlier trials with short-acting relaxin analogues, which suggested that sustained receptor engagement may be necessary to alter the long-term trajectory of heart failure. Preclinical studies in non-human primates have demonstrated that prolonged administration of AZD-3427 leads to significant improvements in cardiac function. A first-in-human Phase 1a/b study confirmed a favorable safety, tolerability, and pharmacokinetic profile, with a terminal half-life of 13-14 days in heart failure patients and early signals of positive hemodynamic and renal effects.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/09/25
Phase 1
Recruiting
2023/02/21
Phase 2
Active, not recruiting
2021/05/18
Phase 1
Withdrawn
2020/11/16
Phase 1
Completed
2018/02/28
Phase 2
Active, not recruiting
2008/06/25
Phase 3
Completed
2007/08/27
Phase 2
Completed
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
2005/11/29
Phase 2
Completed
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
1999/10/19
Phase 2
Completed
National Center for Research Resources (NCRR)

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.